Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
Clinical and Molecular Hepatology · 2024
DOI: 10.3350/cmh.2023.0535 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Molecular Hepatology, 2024. Verfasst von Man-Fung Yuen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Queen Mary Hospital, and State Key Laboratory of Liver Research, The University of Hong Kong, Ho…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Hepatitis B virus, DNA, Viral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Enanta Pharmaceuticals, Inc., AbbVie, Assembly Biosciences.
Abstract (Originalsprache)
Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of EDP-514 in treatment-naive viremic patients with HBeAgpositive or -negative chronic HBV infection.
Methods
Patients with HBsAg detectable at screening and at least 6 months previously were eligible. HBeAg-positive and -negative patients had a serum/plasma HBV DNA level ≥20,000 and ≥2,000 IU/mL, respectively. Twenty-five patients were randomized to EDP-514 200 (n=6), 400 (n=6) or 800 mg (n=7) or placebo (n=6) once daily for 28 days.
Results
A dose-related increase in EDP-514 exposure (AUClast and Cmax) was observed across doses. At Day 28, mean reductions in HBV DNA were –2.9, –3.3, –3.5 and –0.2 log10 IU/mL with EDP-514 200 mg, 400 mg, 800 mg, and placebo groups, respectively. The corresponding mean change from baseline for HBV RNA levels was –2.9, –2.4, –2.0, and –0.02 log10 U/mL. No virologic failures were observed. No clinically meaningful changes from baseline were observed for HBsAg, HBeAg or HBcrAg. Nine patients reported treatment emergent adverse events of mild or moderate severity with no discontinuations, serious AEs or deaths.
Conclusions
In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, Queen Mary Hospital, and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.
- Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Center for Digestive Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
- Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of Gastroenterology and Hepatology, Changhua Christian Hospital, Changhua, Taiwan.
Förderung
- Enanta Pharmaceuticals, Inc.
- AbbVie
- Assembly Biosciences
- Arrowhead Pharmaceuticals
- Arbutus Biopharma
- Bristol Myer Squibb
- Dicerna Pharmaceuticals
- Fujirebio Incorporation
Zitieren
APA
Yuen, M. F., Chuang, W. L., Peng, C. Y., Jeng, W. J., Su, W. W., Chang, T. T., Chen, C. Y., Hsu, Y. C., De La Rosa, G., Ahmad, A., Luo, E., & Conery, A. L. (2024). Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2023.0535
Vancouver
Yuen MF, Chuang WL, Peng CY, Jeng WJ, Su WW, Chang TT, et al. Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients. Clinical and Molecular Hepatology. 2024. doi:10.3350/cmh.2023.0535
BibTeX
@article{Yuen2024,
author = {Yuen, Man-Fung and Chuang, Wan-Long and Peng, Cheng-Yuan and Jeng, Wen-Juei and Su, Wei-Wen and Chang, Ting-Tsung and Chen, Chi-Yi and Hsu, Yao-Chun and De La Rosa, Guy and Ahmad, Alaa and Luo, Ed and Conery, Annie L},
title = {Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients},
journal = {Clinical and Molecular Hepatology},
year = {2024},
doi = {10.3350/cmh.2023.0535}
}
EUVIMED